Press releases

• 
  Thursday, 04 December 2014

  Ferring Pharmaceuticals Announces Grand Opening of U.S. Operations Center

• Tuesday, 25 November 2014

  New data from a pooled analysis shows improved overall survival for prostate cancer patients treated with FIRMAGON® (degarelix) compared to LHRH agonists

• Monday, 20 October 2014

  CORTIMENT®MMX®, a new treatment for ulcerative colitis, receives European approval

• Monday, 13 October 2014

  The Scottish Medicines Consortium (SMC) accepts MYSODELLE® for use in NHS Scotland

• Tuesday, 24 June 2014

  Ferring Pharmaceuticals and Roche collaborate to develop personalised infertility treatment

• 
  Monday, 19 May 2014

  Ferring launches Guts4life, an interactive online resource for people with inflammatory bowel disease

• Friday, 09 May 2014

  New study suggests desmopressin melt improves sleep patterns and psychological functioning of bedwetting children

• Sunday, 13 April 2014

  Real-world patient survey data shows negative impact of nocturia

• Friday, 04 April 2014

  MSD, Ferring Pharmaceuticals and the World Health Organization - Working Together to Prevent Excessive Bleeding in Women after Childbirth

• Wednesday, 05 February 2014

  New paper indicates a potential fifty-percent reduction in cardiac events for prostate cancer patients with pre-existing cardiovascular disease when treated with FIRMAGON® (degarelix) compared to LHRH agonists

Corporate Communications

Ferring International Center S.A.
Ch. de la Vergognausaz 50
CH-1162 Saint-Prex
Switzerland
Tel: +41 58 301 00 00
Fax: +41 58 301 00 10

Email for media enquiries only.
For other queries, please see our Contact page.